


### Amendments to the Claims

1. (Currently amended) A method of treating an infection caused by herpesviridae or poxiridae in a ~~patient-mammalian subject~~ in need thereof comprising administering to said ~~patient-subject~~ an effective amount of at least one ~~Furanose-type carbohydrate compound~~ according to the formula



wherein R<sub>1</sub> is selected from the group consisting of alkyl, aryl, O-aryl, S-aryl, OH, O-alkyl, SH, S-alkyl, NH<sub>2</sub>, N<sub>3</sub>, halogens, -OOCH, and COOH;

wherein R<sub>2</sub> is selected from the group consisting of H, hydroxyl, aliphatic and aromatic ethers and esters ~~and wherein R<sub>1</sub> and R<sub>2</sub> form a ring~~;

wherein R<sub>3</sub> is selected from the group consisting of alkyl, aryl, O-aryl, S-aryl, OH, O-alkyl, SH, S-alkyl, NH<sub>2</sub>, N<sub>3</sub>, halogens, -OOCH, COOH, and acetal rings;


wherein R<sub>4</sub> is selected from the group consisting of alkyl, aryl, O-aryl, S-aryl, OH, O-alkyl, SH, S-alkyl, NH<sub>2</sub>, N<sub>3</sub>, halogens, -OOCH, COOH, and acetal rings ~~and wherein R<sub>3</sub> and R<sub>4</sub> form a ring~~;  
and

wherein X is selected from the group consisting of O, NH and S.

2. (Currently amended) A method as defined in claim 1, wherein R<sub>1</sub> is preferably phenyl; R<sub>2</sub> is preferably selected from the group consisting of -OMe, -OH, and -H; R<sub>3</sub> is preferably selected from the group consisting of -OH, -OAc, -OH, and -OBn, ~~and -H~~; and R<sub>4</sub> is preferably selected from the group consisting of -H, -OAc, and -OBn; or a pharmaceutically active derivative thereof.

3. (Previously amended) A method as defined in claim 1, wherein R<sub>1</sub> and R<sub>2</sub> form a ring comprising -OC(CH<sub>3</sub>)<sub>2</sub>O-.
4. (Previously amended) A method as defined in claim 1, wherein R<sub>3</sub> and R<sub>4</sub> form a ring comprising a moiety preferably selected from the group consisting of -OSi(*i*-Pr)<sub>2</sub>OSi(*i*-Pr)<sub>2</sub>O- and -OCH(Ph)O-.
5. (Canceled)
6. (Canceled)
7. (Canceled)
8. (Previously amended) A method as defined in claim 1, wherein the infection is an infection caused by Cytomegalovirus.
9. (Previously added) A method according to claim 1, wherein the infection is and infection caused by Vaccinia virus.
10. (Previously added) A method according to claim 1, further comprising wherein R<sub>3</sub> and R<sub>4</sub> comprise -OAc.
11. (New) A method according to claim 1, wherein X is selected from the group consisting of O.

12. (New) A method of treating an infection caused by herpesviridae or poxiridae in a mammalian subject in need thereof comprising administering to said subject an effective amount of a compound according to the formula



wherein R<sub>1</sub> is selected from the group consisting of alkyl, aryl, O-aryl, S-aryl, OH, O-alkyl, SH, S-alkyl, NH<sub>2</sub>, N<sub>3</sub>, halogens, -OOCH, and COOH;

wherein R<sub>2</sub> is selected from the group consisting of H, hydroxyl, aliphatic and aromatic ethers and esters;

wherein R<sub>3</sub> is selected from the group consisting of alkyl, aryl, O-aryl, S-aryl, OH, O-alkyl, SH, S-alkyl, NH<sub>2</sub>, N<sub>3</sub>, halogens, -OOCH, COOH, and acetal rings;

wherein R<sub>4</sub> is selected from the group consisting of alkyl, aryl, O-aryl, S-aryl, OH, O-alkyl, SH, S-alkyl, NH<sub>2</sub>, N<sub>3</sub>, halogens, -OOCH, COOH, and acetal rings; and

wherein X is selected from the group consisting of O, NH and S.